ribociclib (LEE011)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Abramson Cancer Center at Penn Medicine

Conditions

Advanced Breast CancerBreast Cancer

Phase 1

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

CompletedNCT01857193

Novartis PharmaceuticalsBreast Cancer

Start: 2013-09-06End: 2020-04-16Updated: 2021-04-13

A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer

CompletedNCT02599363

Abramson Cancer Center at Penn MedicineAdvanced Breast Cancer

Start: 2016-01-31End: 2019-03-12Updated: 2023-11-09

Related Papers

Abstract LB052: Cell cycle synchronization: Biomarker analysis in a phase I trial of alternating ribociclib and paclitaxel in advanced breast cancer

Cancer Research2021-07-01

Abstract CT069: Baseline gene expression patterns of CDK4/6 inhibitor-naïve or -refractory HR+, HER2- advanced breast cancer in the phase Ib study of ribociclib plus everolimus plus exemestane

Cancer Research2018-07-014 citations

Abstract CT087: Ribociclib + endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of molecular alterations

Cancer Research2017-07-011 citations

Abstract P6-13-01: Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2– advanced breast cancer

Cancer Research2016-02-1518 citations

Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer.

Journal of Clinical Oncology2014-05-2022 citations